Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
Machens
Andreas
A
Dralle
Henning
H
D000284:Administration, Oral; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D002116:Calcitonin / Q000378:metabolism; D002272:Carcinoembryonic Antigen / Q000378:metabolism; D018276:Carcinoma, Medullary / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000556:secondary; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome
D001557:Benzenesulfonates; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D002116:Calcitonin; D000077157:Sorafenib